+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Parkinson's Disease Therapeutics Market by Drug Class (Anticholinergics, COMT Inhibitors, Dopamine Agonists), Therapy Type (Medications, Non-Pharmacological Therapies), Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Parkinson's Disease Therapeutics Market by Drug Class (Anticholinergics, COMT Inhibitors, Dopamine Agonists), Therapy Type (Medications, Non-Pharmacological Therapies), Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Parkinson's Disease Therapeutics Market by Drug Class (Anticholinergics, COMT Inhibitors, Dopamine Agonists), Therapy Type (Medications, Non-Pharmacological Therapies), Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5134266
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives seeking insight into the rapidly evolving Parkinson’s Disease Therapeutics Market will find a landscape marked by innovation, shifting market drivers, and deepening segmentation. Leaders must navigate a complex spectrum of advances in treatment modalities, regulatory shifts, supply chain disruptions, and emerging regional strategies to chart a path for sustainable growth and competitive differentiation.

Market Snapshot: Parkinson’s Disease Therapeutics Market in Focus

The Parkinson's Disease Therapeutics Market grew from USD 5.81 billion in 2024 to USD 6.14 billion in 2025. It is expected to continue growing at a CAGR of 5.93%, reaching USD 8.21 billion by 2030. Escalating prevalence alongside demographic shifts, particularly in aging populations, is driving the need for therapies that address both symptoms and underlying pathology. Recent investment trends and scientific advances are fueling new opportunities for market expansion, especially as patient-centric approaches and regulatory engagement reshape access to care and accelerate novel product launches.

Scope & Segmentation of the Parkinson’s Disease Therapeutics Market

  • Drug Classes: Anticholinergics (Benztropine, Trihexyphenidyl), COMT Inhibitors, Dopamine Agonists, Levodopa, MAO-B Inhibitors
  • Therapy Types: Medications, Non-Pharmacological Therapies (Deep Brain Stimulation, Physiotherapy, Speech & Language Therapy)
  • Routes of Administration: Infusion, Injectable, Oral, Transdermal
  • Targeted Areas: Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson's, Idiopathic Parkinson’s, Vascular Parkinsonism
  • Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
  • End Users: Clinics, Home Care, Hospitals
  • Geographic Coverage: Americas (including United States, Canada, Brazil, Argentina, Mexico), Europe, Middle East & Africa (including United Kingdom, Germany, France, Italy, Russia, and more), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, among others)
  • Company Coverage: AbbVie Inc., Biogen Inc., Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, UCB S.A., Novartis AG, BlueRock Therapeutics LP, Denali Therapeutics Inc., and others

Key Takeaways for Decision-Makers

  • Therapeutic innovation is gradually shifting from symptomatic strategies to approaches targeting disease progression, illustrated by the emergence of gene therapy and immunotherapy.
  • Patient-centric models, enabled by digital technologies and real-time health data, are influencing both clinical trial design and ongoing treatment optimization.
  • Supply chain resilience is increasingly vital, given recent tariff adjustments impacting ingredient sourcing and driving operational reassessment.
  • Collaboration among academic, clinical, and industry stakeholders is critical for accelerating translation of preclinical breakthroughs to market-ready solutions.
  • Regional market differences mandate tailored product, pricing, and partnership strategies to ensure regulatory alignment and effective market access.

Tariff Impact: Navigating Supply Chain and Price Dynamics

Tariff policy changes in the United States in 2025 have introduced significant cost pressures for stakeholders importing pharmaceutical ingredients and finished products. These adjustments, targeting essential components from the EU and Asia-Pacific, have exposed vulnerabilities in just-in-time supply models and led to increased inventory and lead time constraints. The resulting pricing volatility is prompting manufacturers to shift toward regionalized production, diversify sourcing, and negotiate new terms with partners to safeguard continuity in patient care. Export-oriented organizations face evolving international markets and must adapt strategies amid shifting global competitiveness.

Methodology & Data Sources Supporting Parkinson’s Disease Therapeutics Market Analysis

This research utilizes both primary and secondary sources to produce a credible, well-validated market assessment. Direct interviews with neurologists, clinical leaders, regulatory specialists, and pharmaceutical executives inform clinical and business perspectives. Secondary research aggregates findings from peer-reviewed journals, regulatory filings, industry reports, and advanced analytics tools for data normalization and scenario modeling. Rigorous triangulation and expert peer review underpin the reliability of the analysis.

Why This Reports Matters to Senior Leaders in the Parkinson’s Disease Therapeutics Space

  • Informs strategic allocation of R&D, manufacturing, and digital health investment to stay ahead of evolving therapeutic targets and care models.
  • Enables risk mitigation through a focused understanding of trade, supply chain, and regulatory challenges across global regions.
  • Supports decision-makers in aligning product development and commercialization with patient-centric, high-value market segments.

Conclusion

Market progress in Parkinson’s Disease Therapeutics is intricately linked to scientific innovation, dynamic supply chain strategies, and market-specific execution. Informed strategic planning will be essential for organizations seeking to deliver sustained value and drive impactful change for patients worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of gene therapy techniques aiming to halt Parkinson’s disease progression
5.2. Expansion of stem cell therapy research targeting neuronal regeneration
5.3. Increasing adoption of personalized medicine in Parkinson’s disease treatment
5.4. Advancements in non-invasive brain stimulation therapies for symptom management
5.5. Growing focus on early diagnostic biomarkers to improve treatment outcomes
5.6. Development of novel drug delivery systems enhancing therapeutic efficacy
5.7. Rising investment in neuroprotective agents to slow disease advancement
5.8. Exploration of microbiome influence on Parkinson’s disease therapeutic approaches
5.9. Integration of digital health technologies for remote patient monitoring
5.10. Collaborative global clinical trials accelerating drug approval processes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Parkinson's Disease Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Anticholinergics
8.2.1. Benztropine
8.2.2. Trihexyphenidyl
8.3. COMT Inhibitors
8.4. Dopamine Agonists
8.5. Levodopa
8.6. MAO-B Inhibitors
9. Parkinson's Disease Therapeutics Market, by Therapy Type
9.1. Introduction
9.2. Medications
9.3. Non-Pharmacological Therapies
9.3.1. Deep Brain Stimulation
9.3.2. Physiotherapy
9.3.3. Speech & Language Therapy
10. Parkinson's Disease Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Infusion
10.3. Injectable
10.4. Oral
10.5. Transdermal
11. Parkinson's Disease Therapeutics Market, by Targeted Area
11.1. Introduction
11.2. Atypical Parkinsonian
11.3. Drug-Induced Parkinsonism
11.4. Genetic Parkinson's
11.5. Idiopathic Parkinson’s
11.6. Vascular Parkinsonism
12. Parkinson's Disease Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.2.1. Hospital Pharmacy
12.2.2. Retail Pharmacy
12.3. Online Pharmacy
13. Parkinson's Disease Therapeutics Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Home Care
13.4. Hospitals
14. Americas Parkinson's Disease Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Parkinson's Disease Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Acadia Pharmaceuticals Inc.
17.3.3. Amneal Pharmaceuticals, Inc.
17.3.4. Amyl Therapeutics SRL
17.3.5. Apotex Inc.
17.3.6. Aspen Neuroscience, Inc.
17.3.7. Biogen Inc.
17.3.8. BlueRock Therapeutics LP
17.3.9. Brainstorm Cell Therapeutics Ltd.
17.3.10. Bristol-Myers Squibb Company
17.3.11. Cerevance, LLC
17.3.12. Cipla Limited
17.3.13. Denali Therapeutics Inc.
17.3.14. Eisai Co., Ltd.
17.3.15. Eli Lilly and Company
17.3.16. F. Hoffmann-La Roche Ltd.
17.3.17. GlaxoSmithKline plc
17.3.18. H. Lundbeck A/S
17.3.19. Lupin Limited
17.3.20. Merck & Co., Inc.
17.3.21. Muna Therapeutics ApS
17.3.22. Novartis AG
17.3.23. Orion Corporation
17.3.24. Otsuka Pharmaceutical Co., Ltd.
17.3.25. Pfizer Inc.
17.3.26. Sumitomo Dainippon Pharma Co., Ltd.
17.3.27. Teva Pharmaceutical Industries Limited
17.3.28. TORRENT PHARMACEUTICALS LTD.
17.3.29. UCB S.A.
17.3.30. Zydus Lifesciences Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY BENZTROPINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY LEVODOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPEECH & LANGUAGE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON’S, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON’S, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 123. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 124. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 125. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 126. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 127. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 130. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 131. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 134. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 135. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 138. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 139. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 144. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 145. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 148. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 149. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 152. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 153. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 236. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 237. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 240. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 241. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 244. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 245. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 248. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 249. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 254. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 255. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 258. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 259. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 262. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 263. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 288. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 289. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 290. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 291. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 292. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 293. ITALY PARKINSON'S DISEASE THERAPEUTI

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amneal Pharmaceuticals, Inc.
  • Amyl Therapeutics SRL
  • Apotex Inc.
  • Aspen Neuroscience, Inc.
  • Biogen Inc.
  • BlueRock Therapeutics LP
  • Brainstorm Cell Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • Cerevance, LLC
  • Cipla Limited
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Muna Therapeutics ApS
  • Novartis AG
  • Orion Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • TORRENT PHARMACEUTICALS LTD.
  • UCB S.A.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.21 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Anticholinergic Drugs Market by Indication (Chronic Obstructive Pulmonary Disease, Gastrointestinal Disorders, Overactive Bladder), Route Of Administration (Inhalation, Oral, Parenteral), Distribution Channel, Product Type - Global Forecast 2025-2030 - Product Image

Anticholinergic Drugs Market by Indication (Chronic Obstructive Pulmonary Disease, Gastrointestinal Disorders, Overactive Bladder), Route Of Administration (Inhalation, Oral, Parenteral), Distribution Channel, Product Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Anticholinergic Drugs Market Report 2025 - Product Image

Anticholinergic Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Anticholinergic Drugs - Global Strategic Business Report - Product Image

Anticholinergic Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Bronchodilators: Market Share, and Growth Analysis by Product Type (Short-Acting Beta Agonists, Long-Acting Beta Agonists, Anticholinergics, Methylxanthines), Application, End User, Technology - Product Image

Bronchodilators: Market Share, and Growth Analysis by Product Type (Short-Acting Beta Agonists, Long-Acting Beta Agonists, Anticholinergics, Methylxanthines), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Targeted Drugs for Parkinson's Disease Market by Therapy Type, Distribution Channel, Route Of Administration, Disease Stage, End User, Patient Age Group, Price Range - Global Forecast 2025-2030 - Product Image

Targeted Drugs for Parkinson's Disease Market by Therapy Type, Distribution Channel, Route Of Administration, Disease Stage, End User, Patient Age Group, Price Range - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From

About the Parkinson Drug Market

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life. The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.